Login to Your Account



Clinic Roundup


Friday, February 3, 2012
• OncoGenex Pharmaceuticals Inc., of Bothell, Wash., reported preliminary results from a Phase II trial that showed 71 percent of chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with OGX-427 plus prednisone had no disease progression at 12 weeks compared with 33 percent of those treated with prednisone alone. The OGX-427 group also had greater declines in prostate-specific antigen and circulating tumor cells.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription